Q1 Earnings Estimate for biote Issued By B. Riley

biote Corp. (NASDAQ:BTMD) – Analysts at B. Riley issued their Q1 2025 EPS estimates for shares of biote in a report released on Thursday, March 13th. B. Riley analyst J. Van. Sinderen expects that the company will earn $0.04 per share for the quarter. The consensus estimate for biote’s current full-year earnings is $0.75 per share. B. Riley also issued estimates for biote’s Q2 2025 earnings at $0.05 EPS, FY2025 earnings at $0.29 EPS, FY2026 earnings at $0.42 EPS and FY2027 earnings at $0.71 EPS.

Separately, Craig Hallum decreased their target price on shares of biote from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th.

biote Trading Up 1.8 %

Shares of NASDAQ BTMD opened at $4.07 on Monday. The firm’s 50-day moving average price is $4.88 and its 200-day moving average price is $5.51. The stock has a market capitalization of $221.15 million, a price-to-earnings ratio of 15.65 and a beta of 1.07. biote has a 12-month low of $3.04 and a 12-month high of $8.44.

Insider Activity

In other news, Director Stephen Mark Cone purchased 38,104 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The shares were bought at an average cost of $3.88 per share, for a total transaction of $147,843.52. Following the acquisition, the director now owns 160,829 shares of the company’s stock, valued at approximately $624,016.52. This trade represents a 31.05 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Guines Llc purchased 750,000 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The shares were purchased at an average price of $3.22 per share, for a total transaction of $2,415,000.00. Following the completion of the acquisition, the insider now directly owns 3,820,938 shares in the company, valued at $12,303,420.36. The trade was a 24.42 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 788,204 shares of company stock worth $2,563,218. 13.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On biote

Several hedge funds have recently added to or reduced their stakes in BTMD. Kanen Wealth Management LLC bought a new position in biote in the 4th quarter worth about $1,791,000. Hillsdale Investment Management Inc. bought a new position in biote in the 4th quarter worth about $1,561,000. Wasatch Advisors LP grew its stake in biote by 8.4% in the 3rd quarter. Wasatch Advisors LP now owns 1,392,809 shares of the company’s stock worth $7,772,000 after acquiring an additional 107,792 shares in the last quarter. Marshall Wace LLP bought a new position in biote in the 4th quarter worth about $543,000. Finally, Trexquant Investment LP grew its stake in biote by 423.1% in the 4th quarter. Trexquant Investment LP now owns 101,757 shares of the company’s stock worth $629,000 after acquiring an additional 82,303 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.